ACOG NASDAQ
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Grapevine, TX 76051
US
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Opaleye Management I | P-Purchase | 14,973 | $8.23 | 2026-10-23 |
| Opaleye Management I | P-Purchase | 17,117 | $8.33 | 2026-10-22 |
| Opaleye Management I | P-Purchase | 14,283 | $8.23 | 2026-10-16 |
| Opaleye Management I | P-Purchase | 22,657 | $8.43 | 2026-10-15 |
| Opaleye Management I | P-Purchase | 19,050 | $8.69 | 2026-10-01 |